BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

674 related articles for article (PubMed ID: 19454272)

  • 1. Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer.
    Bates PJ; Laber DA; Miller DM; Thomas SD; Trent JO
    Exp Mol Pathol; 2009 Jun; 86(3):151-64. PubMed ID: 19454272
    [TBL] [Abstract][Full Text] [Related]  

  • 2. G-quadruplex oligonucleotide AS1411 as a cancer-targeting agent: Uses and mechanisms.
    Bates PJ; Reyes-Reyes EM; Malik MT; Murphy EM; O'Toole MG; Trent JO
    Biochim Biophys Acta Gen Subj; 2017 May; 1861(5 Pt B):1414-1428. PubMed ID: 28007579
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toward G-Quadruplex-Based Anticancer Agents: Biophysical and Biological Studies of Novel AS1411 Derivatives.
    Ogloblina AM; Iaccarino N; Capasso D; Di Gaetano S; Garzarella EU; Dolinnaya NG; Yakubovskaya MG; Pagano B; Amato J; Randazzo A
    Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33096752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AGRO100 inhibits activation of nuclear factor-kappaB (NF-kappaB) by forming a complex with NF-kappaB essential modulator (NEMO) and nucleolin.
    Girvan AC; Teng Y; Casson LK; Thomas SD; Jüliger S; Ball MW; Klein JB; Pierce WM; Barve SS; Bates PJ
    Mol Cancer Ther; 2006 Jul; 5(7):1790-9. PubMed ID: 16891465
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma membrane nucleolin is a receptor for the anticancer aptamer AS1411 in MV4-11 leukemia cells.
    Soundararajan S; Wang L; Sridharan V; Chen W; Courtenay-Luck N; Jones D; Spicer EK; Fernandes DJ
    Mol Pharmacol; 2009 Nov; 76(5):984-91. PubMed ID: 19657047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Study of the Function of G-Rich Aptamers Selected for Lung Adenocarcinoma.
    Hu J; Zhao Z; Liu Q; Ye M; Hu B; Wang J; Tan W
    Chem Asian J; 2015 Jul; 10(7):1519-25. PubMed ID: 25864879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aptamer-based Targeted Delivery of a G-quadruplex Ligand in Cervical Cancer Cells.
    Carvalho J; Paiva A; Cabral Campello MP; Paulo A; Mergny JL; Salgado GF; Queiroz JA; Cruz C
    Sci Rep; 2019 May; 9(1):7945. PubMed ID: 31138870
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A new paradigm for aptamer therapeutic AS1411 action: uptake by macropinocytosis and its stimulation by a nucleolin-dependent mechanism.
    Reyes-Reyes EM; Teng Y; Bates PJ
    Cancer Res; 2010 Nov; 70(21):8617-29. PubMed ID: 20861190
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic applications of AS1411 aptamer, an update review.
    Yazdian-Robati R; Bayat P; Oroojalian F; Zargari M; Ramezani M; Taghdisi SM; Abnous K
    Int J Biol Macromol; 2020 Jul; 155():1420-1431. PubMed ID: 31734366
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AS-1411, a guanosine-rich oligonucleotide aptamer targeting nucleolin for the potential treatment of cancer, including acute myeloid leukemia.
    Mongelard F; Bouvet P
    Curr Opin Mol Ther; 2010 Feb; 12(1):107-14. PubMed ID: 20140822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanistic studies of anticancer aptamer AS1411 reveal a novel role for nucleolin in regulating Rac1 activation.
    Reyes-Reyes EM; Šalipur FR; Shams M; Forsthoefel MK; Bates PJ
    Mol Oncol; 2015 Aug; 9(7):1392-405. PubMed ID: 25911416
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cell surface nucleolin as active bait for nanomedicine in cancer therapy: a promising option.
    Ferrara B; Belbekhouche S; Habert D; Houppe C; Vallée B; Bourgoin-Voillard S; Cohen JL; Cascone I; Courty J
    Nanotechnology; 2021 May; 32(32):. PubMed ID: 33892482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. G-rich oligonucleotides for cancer treatment.
    Bates PJ; Choi EW; Nayak LV
    Methods Mol Biol; 2009; 542():379-92. PubMed ID: 19565914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery and development of anticancer aptamers.
    Ireson CR; Kelland LR
    Mol Cancer Ther; 2006 Dec; 5(12):2957-62. PubMed ID: 17172400
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer-selective antiproliferative activity is a general property of some G-rich oligodeoxynucleotides.
    Choi EW; Nayak LV; Bates PJ
    Nucleic Acids Res; 2010 Mar; 38(5):1623-35. PubMed ID: 20008101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor targeting with a (99m)Tc-labeled AS1411 aptamer in prostate tumor cells.
    Noaparast Z; Hosseinimehr SJ; Piramoon M; Abedi SM
    J Drug Target; 2015; 23(6):497-505. PubMed ID: 25673264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AS1411 binds to nucleolin via its parallel structure and disrupts the exos-miRNA-27a-mediated reciprocal activation loop between glioma and astrocytes.
    Sun X; Zhang W; Gou C; Wang X; Wang X; Shao X; Chen X; Chen Z
    Biochim Biophys Acta Mol Basis Dis; 2024 Jun; 1870(5):167211. PubMed ID: 38701957
    [TBL] [Abstract][Full Text] [Related]  

  • 18. General cell-binding activity of intramolecular G-quadruplexes with parallel structure.
    Chang T; Qi C; Meng J; Zhang N; Bing T; Yang X; Cao Z; Shangguan D
    PLoS One; 2013; 8(4):e62348. PubMed ID: 23638046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterizing Oligonucleotide Uptake in Cultured Cells: A Case Study Using AS1411 Aptamer.
    Reyes-Reyes EM; Bates PJ
    Methods Mol Biol; 2019; 2036():173-186. PubMed ID: 31410797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aptamer-based tumor-targeted drug delivery for photodynamic therapy.
    Shieh YA; Yang SJ; Wei MF; Shieh MJ
    ACS Nano; 2010 Mar; 4(3):1433-42. PubMed ID: 20166743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.